2342 Stock Overview
Develops, distributes, and licenses genetically modified animals and antibodies in Japan.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Transgenic Group Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥235.00 |
| 52 Week High | JP¥294.00 |
| 52 Week Low | JP¥220.00 |
| Beta | 0.67 |
| 11 Month Change | -2.49% |
| 3 Month Change | 6.33% |
| 1 Year Change | -12.96% |
| 33 Year Change | -57.12% |
| 5 Year Change | -43.24% |
| Change since IPO | -89.12% |
Recent News & Updates
Shareholder Returns
| 2342 | JP Biotechs | JP Market | |
|---|---|---|---|
| 7D | 4.9% | 3.2% | 1.1% |
| 1Y | -13.0% | 27.3% | 12.3% |
Return vs Industry: 2342 underperformed the JP Biotechs industry which returned 27.3% over the past year.
Return vs Market: 2342 underperformed the JP Market which returned 12.3% over the past year.
Price Volatility
| 2342 volatility | |
|---|---|
| 2342 Average Weekly Movement | 5.2% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in JP Market | 10.1% |
| 10% least volatile stocks in JP Market | 3.4% |
Stable Share Price: 2342 has not had significant price volatility in the past 3 months compared to the JP market.
Volatility Over Time: 2342's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 236 | Kenji Fukunaga | www.transgenic.co.jp |
Transgenic Group Inc. develops, distributes, and licenses genetically modified animals and antibodies in Japan. It operates through Drug Discovery Support Business and Investment Business segments. The company provides glycan synthesis and analysis services; non-clinical studies for pharmaceuticals, foods, cosmetics, chemical substances, etc., as well as various safety tests for foods, and pharmaceutical agents; and support for bioequivalence test, including clinical trials, pharmacokinetic measurements, and the preparation of clinical trial reports; as well as hospital support services.
Transgenic Group Inc. Fundamentals Summary
| 2342 fundamental statistics | |
|---|---|
| Market cap | JP¥3.90b |
| Earnings (TTM) | -JP¥173.00m |
| Revenue (TTM) | JP¥12.69b |
0.3x
P/S Ratio-22.5x
P/E RatioIs 2342 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2342 income statement (TTM) | |
|---|---|
| Revenue | JP¥12.69b |
| Cost of Revenue | JP¥10.58b |
| Gross Profit | JP¥2.11b |
| Other Expenses | JP¥2.28b |
| Earnings | -JP¥173.00m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 12, 2024
| Earnings per share (EPS) | -10.43 |
| Gross Margin | 16.63% |
| Net Profit Margin | -1.36% |
| Debt/Equity Ratio | 48.7% |
How did 2342 perform over the long term?
See historical performance and comparison